Analysis of PD-L1 Transcriptional Regulation in Ovarian Cancer Cells by Chromatin Immunoprecipitation

  • Yue Zou
  • Sveta Padmanabhan
  • Ivana VancurovaEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2108)


The immune checkpoint molecule, programmed death ligand 1 (PD-L1; B7-H1, CD274), induces T cell apoptosis and tolerance, thus inhibiting the antitumor immunity. PD-L1 expression is increased in many types of cancer, including ovarian cancer (OC), and correlates with poor prognosis. However, the mechanisms that regulate the PD-L1 expression in cancer cells are incompletely understood. The transcriptional regulation of PD-L1 expression is orchestrated by several transcription factors, including NFκB. The human PD-L1 promoter contains five NFκB-binding sites. Interferon-γ (IFNγ) stimulation of OC cells induces p65, and particularly K314/315 acetylated p65 recruitment to all five NFκB-binding sites in PD-L1 promoter, resulting in increased PD-L1 expression. In this chapter, we describe a protocol that uses chromatin immunoprecipitation (ChIP) to analyze the transcriptional regulation of PD-L1 by measuring recruitment of NFκB p65 and K314/315 acetylated p65 to PD-L1 promoter in human OC cells.

Key words

Chromatin immunoprecipitation Interferon-γ NFκB Ovarian cancer p65 PD-L1 Promoter recruitment Transcriptional regulation 



This work was supported by NIH grant CA202775 to I. Vancurova.


  1. 1.
    Huang G, Wen Q, Zhao Y et al (2013) NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS One 8:e61602CrossRefGoogle Scholar
  2. 2.
    Peng J, Hamanishi J, Matsumura N et al (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to Foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75:5034–5045CrossRefGoogle Scholar
  3. 3.
    Gowrishankar K, Gunatilake D, Gallagher SJ et al (2015) Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS One 10:e0123410CrossRefGoogle Scholar
  4. 4.
    Lim SO, Li CW, Xia W et al (2016) Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30:925–939CrossRefGoogle Scholar
  5. 5.
    Bouillez A, Rajabi H, Jin C et al (2017) MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene 36:4037–4046CrossRefGoogle Scholar
  6. 6.
    Maeda T, Hiraki M, Jin C et al (2018) MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer Res 78:205–215CrossRefGoogle Scholar
  7. 7.
    Abiko K, Matsumura N, Hamanishi J et al (2015) IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112:1501–1509CrossRefGoogle Scholar
  8. 8.
    Zou Y, Uddin MM, Padmanabhan S et al (2018) The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells. J Biol Chem 293:15483–15496CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Department of Biological SciencesSt. John’s UniversityQueensUSA

Personalised recommendations